What is TELA Bio?
TELA Bio, Inc. (NASDAQ: TELA) operates at the intersection of advanced material science and surgical innovation. The company specializes in the design, development, and commercialization of proprietary tissue reinforcement materials, most notably its OviTex and OviTex PRS Reinforced Tissue Matrix product lines. By focusing on soft tissue reconstruction, hernia repair, and abdominal wall reconstruction, TELA Bio addresses critical clinical gaps. Their primary value proposition lies in providing economically effective biologic alternatives that mitigate the long-term complications associated with permanent synthetic materials, thereby enhancing patient outcomes and surgical efficiency.
How much funding has TELA Bio raised?
TELA Bio has raised a total of $237.6M across 11 funding rounds:
Unspecified
$6M
Unspecified
$45.4M
Unspecified
$500K
Unspecified
$7.5M
Corporate Investment
$1M
Unspecified
$501K
Unspecified
$10.6M
Stock Offering
$52M
Stock Offering
$48M
Debt
$50M
Unspecified (2013): $6M led by Undisclosed
Unspecified (2014): $45.4M supported by Undisclosed
Unspecified (2014): $500K featuring Undisclosed
Unspecified (2017): $7.5M backed by Undisclosed
Corporate Investment (2018): $1M with participation from ProMedica Innovations Venture Fund
Unspecified (2018): $501K led by Undisclosed
Unspecified (2019): $10.6M supported by Undisclosed
Stock Issuance/Offering (2019): $52M featuring Undisclosed
Stock Issuance/Offering (2020): $48M backed by Undisclosed
Debt (2022): $50M with participation from MidCap Financial
Key Investors in TELA Bio
MidCap Financial
A middle-market focused lender providing flexible, asset-based financing solutions to support the growth and operational needs of healthcare and life sciences companies.
ProMedica Innovations Venture Fund
A corporate venture arm associated with a major health system, focusing on strategic investments in medical technologies that improve patient care and clinical outcomes.
Undisclosed Investors
What's next for TELA Bio?
With the recent infusion of capital, TELA Bio is well-positioned to accelerate its market penetration and expand the clinical adoption of its reinforced tissue matrix portfolio. The company's strategic roadmap likely involves scaling commercial operations, investing in further clinical validation studies, and optimizing supply chain efficiencies to meet the growing demand for advanced biologic repair solutions. As the firm continues to leverage its enterprise-level financing, the focus will remain on solidifying its market share in the competitive reconstructive surgery landscape while maintaining a commitment to reducing long-term patient morbidity through superior material design.
See full TELA Bio company page
